• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

增强恶性肿瘤影像学特征在 BI-RADS-US 4 类乳腺病变的次要分级诊断中的价值。

Value of contrast-enhanced malignancy imaging features in secondary grade diagnosis of BI-RADS-US type 4 breast lesions.

机构信息

Department of Ultrasound Diagnosis Abdomen, Xinjiang Medical University Affiliated First Hospital, Urumqi, Xinjiang, China.

出版信息

Tumori. 2021 Oct;107(5):424-431. doi: 10.1177/0300891620965710. Epub 2020 Oct 30.

DOI:10.1177/0300891620965710
PMID:33124515
Abstract

PURPOSE

To explore the value of contrast-enhanced malignancy imaging features in secondary grade diagnosis of Breast Imaging Reporting and Data System for Ultrasonography (BI-RADS-US) type 4 breast lesions.

METHODS

After initial diagnosis by ultrasound, 124 BI-RADS-US type 4 patients with 130 lesions were examined by contrast-enhanced ultrasound (CEUS) and were classified again before surgery according to five contrast-enhanced malignancy imaging features: inhomogeneous enhancement, peripheral ring-like enhancement, expansive enhancement, internal filling defects, and surrounding radioactive convergence. Lesions with no contrast-enhanced features of malignancy were categorized as type 3; lesions with one, two, or three features of malignancy were categorized as type 4A, 4B, or 4C, respectively; and lesions with four or more indices of malignancy were categorized as type 5. The value of contrasted imaging features of malignancy in diagnosing BI-RADS-US type 4 breast lesions was analyzed.

RESULTS

The accuracy of CEUS diagnosis for type 3 lesions was 93.8% (46/49), 76.9% (10/13) for type 4A, 71.4% (5/7) for type 4B, 75.0% (9/12) for type 4C, and 93.8% (46/49) for type 5 lesions. The sensitivity of CEUS in diagnosing malignant lesions was 90.4%, specificity was 83.6%, and accuracy was 86.9%. CEUS decreased the benign lesion biopsy ratio to 68.5% (46/67) and increased the diagnosis ratio of malignant lesions to 73.0% (46/63).

CONCLUSIONS

CEUS can further optimize the classification of BI-RADS-US type 4 breast lesions and may provide a better reference basis for clinical diagnosis and treatment of those breast lesions.

摘要

目的

探讨超声影像报告与数据系统(BI-RADS-US)4 类乳腺病变增强恶性影像特征在二级诊断中的价值。

方法

124 例 BI-RADS-US 4 类患者的 130 个病灶经超声初诊后,行超声造影(CEUS)检查,术前根据 5 项增强恶性影像特征再次分类:不均匀增强、周边环状增强、膨胀性增强、内部充盈缺损和周围放射性聚集。无恶性增强特征的病灶归类为 3 类;有 1、2、3 项恶性增强特征的病灶分别归类为 4A、4B、4C 类;有 4 项或更多恶性指标的病灶归类为 5 类。分析恶性增强影像特征在诊断 BI-RADS-US 4 类乳腺病变中的价值。

结果

CEUS 诊断 3 类病变的准确率为 93.8%(46/49),4A 类为 76.9%(10/13),4B 类为 71.4%(5/7),4C 类为 75.0%(9/12),5 类为 93.8%(46/49)。CEUS 诊断恶性病变的灵敏度为 90.4%,特异度为 83.6%,准确率为 86.9%。CEUS 将良性病变活检率降低至 68.5%(46/67),增加恶性病变诊断率至 73.0%(46/63)。

结论

CEUS 可进一步优化 BI-RADS-US 4 类乳腺病变的分类,为临床诊断和治疗此类乳腺病变提供更好的参考依据。

相似文献

1
Value of contrast-enhanced malignancy imaging features in secondary grade diagnosis of BI-RADS-US type 4 breast lesions.增强恶性肿瘤影像学特征在 BI-RADS-US 4 类乳腺病变的次要分级诊断中的价值。
Tumori. 2021 Oct;107(5):424-431. doi: 10.1177/0300891620965710. Epub 2020 Oct 30.
2
Application of contrast-enhanced ultrasound in the diagnosis of small breast lesions.超声造影在乳腺小病灶诊断中的应用
Clin Hemorheol Microcirc. 2018;70(3):291-300. doi: 10.3233/CH-170368.
3
A Prospective Multicenter Study on the Additive Value of Contrast-Enhanced Ultrasound for Biopsy Decision of Ultrasound BI-RADS 4 Breast Lesions.对比增强超声在超声 BI-RADS 4 类乳腺病变活检决策中附加价值的前瞻性多中心研究。
Ultrasound Med Biol. 2024 Aug;50(8):1224-1231. doi: 10.1016/j.ultrasmedbio.2024.04.010. Epub 2024 May 24.
4
The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria.超声造影在诊断恶性非肿块型乳腺病变中的作用及诊断标准探讨。
Br J Radiol. 2021 Apr 1;94(1120):20200880. doi: 10.1259/bjr.20200880. Epub 2021 Feb 9.
5
Predictive value of contrast-enhanced ultrasonography and ultrasound elastography for management of BI-RADS category 4 nonpalpable breast masses.超声造影及超声弹性成像对 BI-RADS 分类 4 类触诊阴性乳腺肿块的预测价值。
Eur J Radiol. 2024 Apr;173:111391. doi: 10.1016/j.ejrad.2024.111391. Epub 2024 Feb 28.
6
The Utility of the Fifth Edition of the BI-RADS Ultrasound Lexicon in Category 4 Breast Lesions: A Prospective Multicenter Study in China.第五版 BI-RADS 超声词汇在 4 类乳腺病变中的应用:中国前瞻性多中心研究。
Acad Radiol. 2022 Jan;29 Suppl 1:S26-S34. doi: 10.1016/j.acra.2020.06.027. Epub 2020 Aug 4.
7
The Application Value of Using Semiquantitative and Quantitative Parameters in Multimodal Ultrasound to Distinguish Between Benign and Malignant BI-RADS 4 Lesions.半定量和定量参数在多模态超声鉴别 BI-RADS 4 良恶性病变中的应用价值。
Ultrasound Q. 2024 Jul 5;40(3). doi: 10.1097/RUQ.0000000000000686. eCollection 2024 Sep 1.
8
Contrast-enhanced ultrasound to predict malignant upgrading of atypical ductal hyperplasia.超声造影预测不典型导管增生的恶性升级。
Breast Cancer Res. 2024 Feb 12;26(1):27. doi: 10.1186/s13058-024-01772-2.
9
Diagnosis of sub-centimetre breast lesions: combining BI-RADS-US with strain elastography and contrast-enhanced ultrasound-a preliminary study in China.乳腺亚厘米级病变的诊断:联合乳腺影像报告和数据系统-超声(BI-RADS-US)、应变弹性成像及超声造影在中国的初步研究
Eur Radiol. 2017 Jun;27(6):2443-2450. doi: 10.1007/s00330-016-4628-4. Epub 2016 Oct 19.
10
Breast non-mass-like lesions on contrast-enhanced ultrasonography: Feature analysis, breast image reporting and data system classification assessment.超声造影下乳腺非肿块样病变:特征分析、乳腺影像报告和数据系统分类评估
World J Clin Cases. 2020 Feb 26;8(4):700-712. doi: 10.12998/wjcc.v8.i4.700.

引用本文的文献

1
A combined clinical-ultrasound radiomics model for differentiating benign and malignant BI-RADS category 4 breast masses.一种用于鉴别BI-RADS 4类乳腺肿块良恶性的临床-超声影像组学联合模型。
Am J Transl Res. 2025 Aug 15;17(8):6370-6380. doi: 10.62347/SBKU2090. eCollection 2025.
2
An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.一种通过ctDNA甲基化测序进行乳腺肿瘤鉴别诊断的方法。
Cancer Med. 2025 Jun;14(12):e71004. doi: 10.1002/cam4.71004.